ELVN
Enliven Therapeutics, Inc.NASDAQHealthcare$38.83+2.75%ClosedMarket Cap: $2.32B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.80
P/S
0.00
EV/EBITDA
-19.49
DCF Value
$1.70
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.2%
ROA
-21.8%
ROIC
-26.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-29.7M | $-0.45 |
| FY 2025 | $0.00 | $-103.7M | $-1.83 |
| Q3 2025 | $0.00 | $-20.1M | $-0.32 |
| Q2 2025 | $0.00 | $-25.3M | $-0.49 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-03-26MizuhoOutperform
2026-03-25HC Wainwright & Co.Buy
2025-07-02BairdOutperform
2025-06-16Jones TradingBuy
2025-05-16Trading Activity
Insider Trades
View AllCollins Helen Louiseofficer: CHIEF MEDICAL OFFICER
SellFri Mar 27
Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER
SellFri Mar 27
Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER
SellThu Mar 19
Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER
SellThu Mar 19
Collins Helen Louiseofficer: CHIEF MEDICAL OFFICER
SellWed Mar 11
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.49
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.